Questions related to Bronchiectasis
Many published studies showed the role of Neutrophil Elastaste (NE) in sputum to bronchiectastic patients. NE in sputum or BAL could present neutrophil inflammation on airways of bronchiectastic patients but why we do not use the count of neutrophil in sputum or BAL to prognosis for those patients?
Thanks for your help.
It is recommended to use inhaled topramycin in non cystic bronchiectasis but is it recommended in non cystic even without isolation of P.aurginosa
I am trying a lot to find about how many bronchiectasis patient suffer from neutrophil based inflammation, I know that approximately all the bronchiectasis patients suffer from neutrophil based inflammation but I am not getting any reference that can be give me solid evidence about exact proportion. Please answer with reference.
We work in a pediatric facility where IHCs are very important and naturally fixation is critical. We NEVER rush our tissues and the best quality is of utmost importance. But our PA has developed lung issues from the formalin we believe and though we have ventilated as much as possible and all the badge testing comes back with minimal exposure results his symptoms persist. Any opinions on formalin substitutes?
In research articles and reviews which was conducted with chronic pulmonary diseases such as COPD and cystic fibrosis, for assessing physical activity researchers generally used Actigraph GT3X, DynaPort Minimod and SenseWear accelerometers. By using accelerometers more information will be concluded other than using pedometers. Is there any other validated and low cost method to assess physical activity?
From the abstract, lobar analysis on extent (on a six-point scale) of emphysema, the presence of bronchiectasis, airway wall thickening, and tracheal abnormalities on volumetric CT images was done by thoracic radiologists. So the extent of the abnormality at each lobar level will range from 0 to 6, right? Next, the extent of emphysema, airway wall thickening, and luminal area were quantified at the lobar level by using commercial software. Does this mean the sum of the extent of 0-6 at each level is used to quantify the extent of the feature/abnormalities at the lobar level? If not, what is the variable used to combine the extent (0-6) that has been analyzed by the radiologist for quantification at lobar level. Also, what is the commercial software used to get the value, and do you use the term score to refer to the extent of the features,i.e emphysema, airway wall thickening and etc.?